Benefit-risk assessment: to quantify or not to quantify, that is the question.
about
Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatmentNumber needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis.Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
P2860
Benefit-risk assessment: to quantify or not to quantify, that is the question.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Benefit-risk assessment: to quantify or not to quantify, that is the question.
@en
Benefit-risk assessment: to quantify or not to quantify, that is the question.
@nl
type
label
Benefit-risk assessment: to quantify or not to quantify, that is the question.
@en
Benefit-risk assessment: to quantify or not to quantify, that is the question.
@nl
prefLabel
Benefit-risk assessment: to quantify or not to quantify, that is the question.
@en
Benefit-risk assessment: to quantify or not to quantify, that is the question.
@nl
P2093
P2860
P356
P1476
Benefit-risk assessment: to quantify or not to quantify, that is the question.
@en
P2093
Bennett Levitan
Jesse A Berlin
Zhong Yuan
P2860
P304
P356
10.1002/PDS.2149
P577
2011-06-01T00:00:00Z